Cancer Vaccines Launch Pad (CVLPP

Concepts

• health services
• leeds
• personalised cancer vaccine research trials
• cancer patients
• one cancer vaccine clinical trial
• launch
• cancer
• cvlpp
• pad
• vaccine

Location

Leeds

Description

The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the National Institute of Health Research (NIHR) and Genomics England (GEL), with the aim to facilitate access to personalised cancer vaccine research trials. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister. See link (https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine... the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial.The CVLP is company agnostic and is being set up in a phased approach with a small number of Trusts to test the pathway from September 2023. For the first phase, the CVLP is supporting one cancer vaccine clinical trial.

Total Quantity or Scope

As per short description

Renewal Options

Up to a single 12 month extension from 01/04/2025. Any extension period is subject to approval of NHS England.

CPV Codes

• 85100000 - Health services

Indicators

• Bids should cover the whole contract.
• Renewals are available.
• Award on basis of price and quality.

Other Information

It is likely that three to four additional trials will be brought into the CVLP during 2024.NHS England is looking for a supplier to provide the digital infrastructure and clinical liaison function to manage the end-to-end pathway of the CVLP for up to 2000 patients until March 2025.Initial term is 15 months to a maximum value of £1,400,000. There is provision for a potential 12 month extension up to a maximum value £700k but this is subject to approvals by NHSE.To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:Phone: 0800 9956035E-mail: support-health@atamis.co.uk